Literature DB >> 11046103

A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog.

A Abelö1, U G Eriksson, M O Karlsson, H Larsson, J Gabrielsson.   

Abstract

A turnover model for irreversible inhibition of gastric acid secretion by omeprazole in gastric fistula dogs was developed using data from studies with both short- and long-term measurement periods. In the short-term experiments, after stimulation of acid secretion with histamine, the dogs were infused i.v. with omeprazole and acid secretion was measured for 5 h. Dose and infusion times were varied to produce different concentration-time profiles and schedule dependence in the inhibitory effect of omeprazole was observed. In the long-term experiments, dogs were given single intraduodenal doses, which inhibited the acid secretion for several days. Combining the short-term and long-term data allowed the observation of a biphasic recovery of acid secretion that was described by the turnover model. Second order association rate constants (k(ome)) for the covalent binding of omeprazole to H(+),K(+)-ATPase were estimated to 11 and 3.0 l/micromol/h for the i.v. and intraduodenal experiments, respectively. The apparent turnover rate constant of the enzyme (k(out)) was 0.013 h(-1) and the corresponding half-life of inhibition of acid secretory capacity was 54 h. The potency, calculated as k(out) over k(ome), was 4.3 and 1.2 nM for the intraduodenal and i.v. doses, respectively. Allometric scaling of the model resulted in trustworthy predictions for observations previously done in humans. The model predicted a good correlation between maximal inhibitory effect and exposure (area under the plasma concentration curve). The time dependence in this relation was also predicted by the model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046103

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  A dynamical systems analysis of the indirect response model with special emphasis on time to peak response.

Authors:  Lambertus A Peletier; Johan Gabrielsson; Jacintha den Haag
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

2.  Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.

Authors:  Meindert Danhof; Gunnar Alvan; Svein G Dahl; Jochen Kuhlmann; Gilles Paintaud
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

3.  Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.

Authors:  Philipp Haselmayer; Montserrat Camps; Lesley Liu-Bujalski; Ngan Nguyen; Federica Morandi; Jared Head; Alison O'Mahony; Simone C Zimmerli; Lisa Bruns; Andrew T Bender; Patricia Schroeder; Roland Grenningloh
Journal:  J Immunol       Date:  2019-04-15       Impact factor: 5.422

Review 4.  Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence.

Authors:  Yuko Akazawa; Daisuke Fukuda; Yutaka Fukuda
Journal:  Therap Adv Gastroenterol       Date:  2016-09-22       Impact factor: 4.409

5.  Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole.

Authors:  Angela Abelö; Björn Holstein; Ulf G Eriksson; Johan Gabrielsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

6.  Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans.

Authors:  Jasper Stevens; Bart A Ploeger; Margareta Hammarlund-Udenaes; Gunilla Osswald; Piet H van der Graaf; Meindert Danhof; Elizabeth C M de Lange
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-12       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.